PRLR and breast cancer: Given the possible involvement of PRLR in BC, some studies proposed that PRLR could serve as a therapeutic target for BC, and developed PRLR antibody–drug conjugates, such as REGN2878–DM1, antibody targeting hPRLr-ECD, and ABBV-176, among others [37,38,39].